ASP3026 , ≥98% , 1097917-15-1

CAS NO.：1097917-15-1

Empirical Formula: C29H40N8O3S

Molecular Weight: 580.74

MDL number: MFCD21609265

EINECS: 200-258-5

PRODUCT Properties

• Boiling point: 794.3±70.0 °C(Predicted)
• Density: 1.276
• storage temp.: Store at -20°C
• solubility: insoluble in H2O; ≥14.53 mg/mL in DMSO; ≥4.9 mg/mL in EtOH with gentle warming and ultrasonic
• form: solid
• pka: 8.14±0.42(Predicted)
• color: White to off-white

Description and Uses

ASP3026 is an ATP-competitive, second-generation ALK inhibitor (IC₅₀ = 3.5 nM) that also inhibits ROS (IC₅₀ = 8.9 nM) and ACK (IC₅₀ = 5.8 nM). It inhibits neuroblastoma-activating ALK mutants F1174L (IC₅₀ = 10 nM) and R1275Q (IC₅₀ = 5.4 nM) and demonstrates antitumor activity in xenograft mouse models. ASP3026 has been shown to overcome crizotinib resistance in non-small cell lung cancer, and is currently being evaluated in clinical trials of patients with ALK-positive solid tumors.

ASP3026 is a novel and selective anaplastic lymphoma kinase (ALK) inhibitor that shows potent anti-tumor activities. ASP3026 also shows potential efficacy for non-small cell lung cancer (NSCLC) and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality. Potent ALK inhibitor.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning